FDA Commissioner Marty Makary Resigns Following Industry Pressure
FDA Commissioner Marty Makary resigns amid agency turmoil, staff exodus, and pressure over vaccines and drug approvals.Summary
FDA Commissioner Marty Makary has resigned following a turbulent tenure marked by significant leadership turnover and inconsistent regulatory decision-making. His departure comes amid escalating criticism from pharmaceutical stakeholders, anti-abortion groups, and vaping industry lobbyists. Under his leadership, the agency experienced a high rate of attrition among senior career officials, with many citing a climate of dysfunction and the alleged override of scientific principles by political interests. The resignation highlights a period of regulatory unpredictability, exemplified by conflicting decisions such as the rejection of Replimune's melanoma therapy despite prior staff alignment and disputes over vaccine eligibility. Makary's initiatives to streamline drug reviews remain vulnerable without formal rulemaking, leaving the agency's future direction uncertain as Kyle Diamantas assumes the role of acting commissioner.
(Source：PharmTech.com)
